Theme 4. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 75-78

  Visco Comandini, Ubaldo ^a   Balotta, Claudia ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; PROTEINASE; VIRUS DNA;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC KIT; DRUG SENSITIVITY; EUROPE; GENE MUTATION; GENETIC DATABASE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; POLYMERASE CHAIN REACTION; RELIABILITY; STRAIN DIFFERENCE; TREATMENT FAILURE; UNITED STATES; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS TRANSMISSION; ANTIBIOTIC RESISTANCE; CLASSIFICATION; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENETICS; MALE; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; VIROLOGY;

ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 1842852044     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wolinsky S, Korber B, Neumann A, Daniels M, Kunstman K, Whetsell A, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996: 272: 537-42.
2. Kuiken C, Foley B, Hahn B, Marx P, McCutchan F, Mellors J, et al. Human Retroviruses and AIDS. Los Alamos: Los Alamos National Laboratory; 1999 (Group TBaB, ed. LANL. HIV Sequence Database. hiv-web. http://www.hiv.lanl.gov/2001
3. Balotta C, Facchi G, Violin M, Van Dooren S, Cozzi-Lepri A, Forbici F, et al. ICONA Study Group. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27: 499-505.
4. Alacus A, Lidman K. Bjorkman A. Giesecke J, Albert J. Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D. AIDS 1999; 13: 901-7.
5. Björndal Å, Sönnerborg A, Tsherning C, Albert J, Fenyö E. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retrovir 1999; 15: 647-53.
6. Overbaugh J, Sagar M, Benki S, Lavreys L, Richardson B, Beaten J, Long E, et al. Viral and host factors in HIV-1 transmission and pathogenesis. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002.
7. Vergne L, Peeters M. Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38: 3919-25.
8. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke J, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1 infected African patients. AIDS 2001; 15: 1493-502.
9. Baxter J, Mayers D, Wentworth D, Neaton J, Hoover M, Winters M, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14: F83-93.
10. Clevenbergh P, Durant JH, del Giudice R Mondain V, Montagne N. Schapiro J, et al. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antivir Ther 2000; 5: 65-70.
11. Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, Tamalet C. Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type I subtypes: how to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis 2001; 183: 1311-7.
12. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type I subtypes A through J. J Acquir Immune Defic Syndr 2001; 28: 254-8.
13. Jagodzinski L, Cooley J, Kelly S, Michael N. Performance of the TRUGENE HIV-1 genotyping kit and the Applied Biosystems HIV-1 genotyping system in sequence-based analysis of non-B HIV-1 subtypes. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002.
14. Holguin A, Rodes B, Soriano V. Protease gene analysis of HIV type 1 non-B subtypes in Spain. AIDS Res Hum Retrovir 2000; 16: 1395-403.
15. Gomes P, Diogo I, Goncalves M, Carvalho P, Cabanas J, Lobo M, Camacho R. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002.
16. Grossman Z, Maayan S, Auerbuch D, Sahar E, Levi I, Lorber M, et al. Longitudinal analysis of RT and protease mutations among Israeli patients infected with HIV subtype C. In: 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24 28 February 2002.
17. Yerly S, Vora S, Rizzardi P. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-92.
18. de Mendoza C, del Romero J, Rodriguèz C. Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Spain. 9th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 24-28 February 2002. Abstract 371-M.
19. Robertson DL, Anderson JP. Bradac JA. HIV-1 nomenclature proposal. Science 2000; 288: 55-6.
20. Peeters M. Recombinant HIV sequences: their role in the global epidemic. In: Human retroviruses and AIDS compendium: a compilation and analysis of nucleic acid and aminoacid sequences. Los Alamos: Los Alamos National Laboratory; 2001.
21. Becker-Pergola G, Kataaha P, Jhonston-Dow L. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retrovir 2000; 16: 807-13.
22. Gonzales MJ, Machekano R, Shafer RW. HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001; 184: 998-1006.
23. Pieniazek D, Rayfield M. Hu DJ. Protease sequences from HIV-1 group M subtypes A H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000; 14: 1489-95.
24. Cornelissen M. van dB, Zorgdrager F. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997; 71: 6348-58.
25. Dileanis J, Kunstman K, Wolinsky S. Multi-center testing of the Applied Biosystems ViroSeq HIV-1 genotyping kit version 2. XIII International AIDS Conference, Durban, South Africa, 2000.
26. Eshleman SH, Mraena M, Guay L. Selection of nevirapine resistance (NVPR) mutations in Ugandan women and infants receiving NVP prophylaxis to prevent HIV-1 vertical transmission (HIVNET-012). 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4-8 February 2001. Abstract 516.
27. Marlowe N, Hoo B, Dileanis J. Performance of PE biosystems version 2 HIV genotyping system for antiretroviral drug resistance testing using the HIV-1 subtype panel (group M). XIII International AIDS Conference, Durban, South Africa, 2000. TuPeA3009.
28. Lambert C, Fontane E, Servais J. Drug resistance-related mutations in the pol gene of non-subtype B HIV-1 patient strains. Antivir Ther 2000; 5 (Suppl 3).
29. Brown AJ, Precious HM, Whitcomb J. Reduced susceptibility of HIV-1 to protease inhibitors from patients with primary HIV infection by three distinct routes. 8th Conference on Retroviruses and Opportunistic Infections, Chicago, USA, 4-8 February 2001. Abstract 424.
30. Descamps D, Apetrei C, Collin G. Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998; 12: 1109-11.
31. King RW, Winslow DL, Garber S. Identification of a clinical isolate of HIV-1 with an isoleucine at position 82 of the protease which retains susceptibility to protease inhibitors. Antivir Res 1995; 28: 13-24.
32. Descamps D, Collin G, Letourneur F. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997; 71: 8893-8.
33. Quinones-Mateu ME, Soriano V, Domingo E. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. Virology 1997; 236: 364-73.
34. Palmer S, Alaeus A, Albert J. Drug susceptibility of subtypes A, B, C, D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retrovir 1998; 14: 157-62.
35. Shafer RW, Chuang TK, Hsu P. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retrovir 1999; 15: 65-9.
36. Shafer RW, Eisen JA, Merigan TC. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997; 71: 5441-8.
37. Tanuri A, Vicente AC, Otsuki K. Genetic variations and susceptibilities to other protease inhibitors among subtype B and F isolates in Brazil. Antimicrob Agents Chemother 1999; 43: 253-8.
38. Apetrei C, Descamps D, Collin G. Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol 1998; 72: 3534-8.
39. Caride E, Brindeiro R, Hertogs K. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type 1 found in Brazilian patients failing HAART Virology 2000; 275: 107-15.
40. Weidle PJ, Kityo CM, Mugyenyi P. Resistance to antiretroviral therapy among patients in Uganda. J Acquir Immun Defic Syndr 2001; 26: 495-500.
41. de Bethune MP, Hertogs K, Heyndrikx L. Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A-H) and O, differ from subtype B? Antivir Ther 1999; 4 (Suppl 1): 33. Abstract 49.